Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Mylan NV, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Mylan NV, Medical Equipment Deals By Type, 2012 to YTD 2018 7
Mylan NV, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Mylan NV, Medical Equipment, Deals By Market, 2012 to YTD 2018 9
Mylan NV, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
Mylan NV, Medical Equipment, Deal Details 11
Venture Financing 11
Zyomyx Raises US$6 Million In First Closing Of Series 2 Preferred Financing 11
Partnerships 12
Mylan Teoranta Enters into Licensing Agreement with Contura 12
Mylan Enters into Partnership with Atomo Diagnostics 13
Mylan Enters Into Distribution Agreement With Zyomyx For CD4 T-Cell Count Test 14
Phosphagenics Enters Into Licensing Agreement With Agila Specialties For TPM Technology 16
Mylan Specialty Enters Into Licensing Agreement With Pfizer For EpiPen 17
Debt Offering 18
Mylan Prices Private Placement of 5.2% Notes Due 2048 for USD750 Million 18
Mylan Prices Private Placement of 4.55% Notes Due 2028 for USD750 Million 19
Mylan Raises USD551.6 Million in Public Offering of Bonds Due 2020 20
Mylan Raises USD1 Billion in Private Placement of 5.25% Notes Due 2046 21
Mylan Raises USD2.25 Billion in Private Placement of 3.95% Notes Due 2026 22
Mylan Raises USD1 Billion in Private Placement of 2.5% Notes Due 2019 23
Mylan Raises USD2.25 Billion in Private Placement of 3.15% Notes Due 2021 24
Acquisition 25
Mylan Acquires Meda for USD9.42 Billion 25
Mylan NV – Key Competitors 27
Mylan NV – Key Employees 28
Mylan NV – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 36
Strategy And Business Planning 36
Sep 25, 2018: Mylan signs HIV test commercialisation deal with Atomo Diagnostics 36
Financial Announcements 37
Aug 08, 2018: Mylan reports second quarter 2018 results and updates 2018 guidance 37
May 09, 2018: Mylan Reports First Quarter 2018 Results and Reaffirms 2018 Guidance 42
Feb 28, 2018: Mylan Reports Full Year and Fourth Quarter 2017 Results and Provides 2018 Guidance 44
Nov 06, 2017: Mylan Reports Third Quarter 2017 Results and Updates 2017 Guidance 46
Aug 09, 2017: Mylan Reports Second Quarter 2017 Results and Updates 2017 Guidance 48
May 10, 2017: Mylan Reports First Quarter 2017 Results 52
Mar 01, 2017: Mylan Reports Fourth Quarter and Full Year 2016 Results and Provides 2017 Guidance 54
Corporate Communications 56
May 14, 2018: Mylan and West Virginia University Join Forces to Inspire West Virginia Youth Through STEM-CARE 56
Feb 26, 2018: 16-Year Veteran Director Wendy Cameron to Retire from Mylan Board after 2018 AGM 58
Sep 13, 2017: Mylan Names Dennis Zeleny as Chief Human Relations Officer 59
May 01, 2017: Mylan Nominates Sjoerd Vollebregt for Election to Board of Directors 60
Mar 28, 2017: Mylan Names Former SEC Commissioner Daniel Gallagher as Chief Legal Officer 61
Legal and Regulatory 62
Jun 28, 2018: Mylan Statement: Morgantown Operations 62
Nov 10, 2017: Mylan Announces Voluntary Delisting from the Tel Aviv Stock Exchange 63
Oct 31, 2017: Mylan Provides Statement in Response to Announcement of Proposed Amendments to Civil Complaint 64
Product News 65
Apr 11, 2018: Investor Day Highlights Durability of Mylan’s Global Platform 65
Appendix 66
Methodology 66
About GlobalData 66
Contact Us 66
Disclaimer 66
Mylan NV, Medical Equipment, Key Facts, 2017 2
Mylan NV, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Mylan NV, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Mylan NV, Medical Equipment Deals By Type, 2012 to YTD 2018 7
Mylan NV, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Mylan NV, Deals By Market, 2012 to YTD 2018 9
Mylan NV, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
Zyomyx Raises US$6 Million In First Closing Of Series 2 Preferred Financing 11
Mylan Teoranta Enters into Licensing Agreement with Contura 12
Mylan Enters into Partnership with Atomo Diagnostics 13
Mylan Enters Into Distribution Agreement With Zyomyx For CD4 T-Cell Count Test 14
Phosphagenics Enters Into Licensing Agreement With Agila Specialties For TPM Technology 16
Mylan Specialty Enters Into Licensing Agreement With Pfizer For EpiPen 17
Mylan Prices Private Placement of 5.2% Notes Due 2048 for USD750 Million 18
Mylan Prices Private Placement of 4.55% Notes Due 2028 for USD750 Million 19
Mylan Raises USD551.6 Million in Public Offering of Bonds Due 2020 20
Mylan Raises USD1 Billion in Private Placement of 5.25% Notes Due 2046 21
Mylan Raises USD2.25 Billion in Private Placement of 3.95% Notes Due 2026 22
Mylan Raises USD1 Billion in Private Placement of 2.5% Notes Due 2019 23
Mylan Raises USD2.25 Billion in Private Placement of 3.15% Notes Due 2021 24
Mylan Acquires Meda for USD9.42 Billion 25
Mylan NV, Key Competitors 27
Mylan NV, Key Employees 28
Mylan NV, Other Locations 29
Mylan NV, Subsidiaries 30
List of Figures
Mylan NV, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Mylan NV, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Mylan NV, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Mylan NV, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Mylan NV, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Mylan NV, Medical Equipment, Deals by Type, 2012 to YTD 2018 7
Mylan NV, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Mylan NV, Medical Equipment, Deals by Market, 2012 to YTD 2018 9